BOTH CIRCULATING AND CLOT-BOUND PLASMINOGEN-ACTIVATOR INHIBITOR-1 INHIBIT ENDOGENEOUS FIBRINOLYSIS IN THE RAT

被引:36
作者
REILLY, CF
FUJITA, T
MAYER, EJ
SIEGFRIED, ME
机构
[1] Department of Pharmacology, Merck Sharp and Dohme Res. Labs., West Point, PA
[2] Department of Pharmacology, Merck Sharp and Dohme Res. Labs., West Point
来源
ARTERIOSCLEROSIS AND THROMBOSIS | 1991年 / 11卷 / 05期
关键词
PLASMINOGEN ACTIVATOR INHIBITOR-1; FIBRIN; THROMBOSIS; FIBRINOLYSIS; PLASMINOGEN ACTIVATORS; TISSUE-TYPE PLASMINOGEN ACTIVATOR;
D O I
10.1161/01.ATV.11.5.1276
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of both clot-bound and circulating plasminogen activator inhibitor-1 (PAI-1) on endogenous fibrinolysis were investigated in a rat model of pulmonary embolism. Iodine-125 fibrin(ogen)-labeled blood-clot homogenates were delivered through the left jugular vein to the lung microvasculature, and the subsequent extent of the clot lysis was monitored by measuring the release of I-125-fibrin degradation products (FDPs) into the blood. Clots that had incorporated activated PAI-1 ex vivo were subsequently protected from dissolution in vivo in a dose-responsive manner (half-maximal concentration [IC50] = 4.3-mu-g/ml). PAI-1-containing clots also resisted lysis, as measured by the release of the specific FDP D-dimer. Plasma levels of plasminogen activator (PA) and PAI activity were unaltered by administration of PAI-1-containing clots, and the clot-protective effects of clot-bound PAI-1 were reversed by exogenous tissue-type plasminogen activator administration. Clot lysis was also inhibited in a dose-responsive manner (IC50 = 58-mu-g/kg) by intravenous bolus delivery of activated PAI-1 to the circulation. The clot-protective effects of circulating PAI-1 were correlated with dose-dependent increases in plasma PAI-1 antigen and activity levels and decreases in plasma PA levels (IC50 = 37-mu-g/ml). There was no evidence of any accumulation of circulating PAI-1 in the lungs. Latent PAI-1, whether delivered with or delivered after the clot homogenates, did not affect the clot-lytic process. Activated and latent PAI-1 was cleared from the circulation in a monophasic manner, with a half-life of approximately 32 and 7 minutes, respectively. The results indicate that both clot-bound and circulating PAI-1 are potent inhibitors of fibrinolysis in vivo. Clot-bound PAI-1 may inhibit PAs in the immediate vicinity of the clots, whereas circulating PAI-1 may act systemically by controlling overall levels of PAs present in the blood.
引用
收藏
页码:1276 / 1286
页数:11
相关论文
共 38 条
[1]   CORRELATIONS BETWEEN T-PA AND PAI-1 ANTIGEN AND ACTIVITY AND T-PA/PAI-1 COMPLEXES IN PLASMA OF CONTROL SUBJECTS AND OF PATIENTS WITH INCREASED T-PA OR PAI-1 LEVELS [J].
ALESSI, MC ;
JUHANVAGUE, I ;
DECLERCK, PJ ;
ANFOSSO, F ;
GUEUNOUN, E ;
COLLEN, D .
THROMBOSIS RESEARCH, 1990, 60 (06) :509-516
[2]   ELEVATED LEVELS OF THE RAPID INHIBITOR OF PLASMINOGEN-ACTIVATOR (T-PAI) IN ACUTE MYOCARDIAL-INFARCTION [J].
ALMER, LO ;
OHLIN, H .
THROMBOSIS RESEARCH, 1987, 47 (03) :335-339
[3]  
AZNAR J, 1988, BRIT HEART J, V59, P535
[4]  
CHANDLER WL, 1990, BLOOD, V76, P930
[5]  
CHMIELEWSKA J, 1986, CLIN CHEM, V32, P482
[6]   FIBRINOLYSIS AND ATHEROSCLEROSIS [J].
COLLEN, D ;
JUHANVAGUE, I .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1988, 14 (02) :180-183
[7]   GENERATION IN PLASMA OF A FAST-ACTING INHIBITOR OF PLASMINOGEN-ACTIVATOR IN RESPONSE TO ENDOTOXIN STIMULATION [J].
COLUCCI, M ;
PARAMO, JA ;
COLLEN, D .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (03) :818-824
[8]  
DECLERCK PJ, 1988, BLOOD, V71, P220
[9]  
DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454
[10]  
DIEVAL J, 1991, BLOOD, V77, P528